AVANIR Pharmaceuticals (AVNR)

16.96
0.00 (0.00)
NASDAQ : Health Care
Prev Close 16.96
Open 16.96
Day Low/High 16.96 / 16.98
52 Wk Low/High 3.02 / 17.05
Volume 8.44M
Avg Volume 6.29M
Exchange NASDAQ
Shares Outstanding 193.76M
Market Cap 3.29B
EPS -0.31
P/E Ratio N/A
Div & Yield N.A. (N.A)
Perilous Reversal Stock: AVANIR Pharmaceuticals (AVNR)

Perilous Reversal Stock: AVANIR Pharmaceuticals (AVNR)

Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "perilous reversal" (up big yesterday but down big today) candidate

4 Biotech Stocks Under $10 to Watch

4 Biotech Stocks Under $10 to Watch

Keep these under-$10 biotech stocks on your radar.

AVNR January 2015 Options Begin Trading

AVNR January 2015 Options Begin Trading

Investors in Avanir Pharmaceuticals, Inc. saw new options become available today, for the January 2015 expiration.

Insider Trading Alert - AVNR, ALK, BIIB, VRX And RAI Traded By Insiders

Insider Trading Alert - AVNR, ALK, BIIB, VRX And RAI Traded By Insiders

Stocks with insider trader activity include AVNR, ALK, BIIB, VRX and RAI

First Week Of AVNR November 16th Options Trading

First Week Of AVNR November 16th Options Trading

Investors in Avanir Pharmaceuticals, Inc. saw new options become available this week, for the November 16th expiration.

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Perilous Reversal" Stock

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "dead cat bounce" (down big yesterday but up big today) candidate

'Mad Money' Lightning Round: Primerica's a Long-Term Play

'Mad Money' Lightning Round: Primerica's a Long-Term Play

Avanir Pharmaceuticals is a great speculative biotech, Cramer said, but he's worried about DaVita.

Cramer's 'Mad Money' Recap: China and U.S. Stocks

Cramer's 'Mad Money' Recap: China and U.S. Stocks

After years of dragging U.S. stocks lower, a turn is at hand overseas, Cramer said.

First Week Of October 19th Options Trading For Avanir Pharmaceuticals (AVNR)

First Week Of October 19th Options Trading For Avanir Pharmaceuticals (AVNR)

Investors in Avanir Pharmaceuticals, Inc. saw new options become available this week, for the October 19th expiration.

Cramer's 'Mad Money' Recap: A Murphy's Law Market

Cramer's 'Mad Money' Recap: A Murphy's Law Market

What could go wrong, did, said Cramer. It's time to take some profits.

First Week Of March 2014 Options Trading For Avanir Pharmaceuticals (AVNR)

First Week Of March 2014 Options Trading For Avanir Pharmaceuticals (AVNR)

Investors in Avanir Pharmaceuticals, Inc. saw new options begin trading this week, for the March 2014 expiration.

Biotech Stock Mailbag: Apricus, Avanir

Biotech Stock Mailbag: Apricus, Avanir

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

July Options Now Available For Avanir Pharmaceuticals (AVNR)

July Options Now Available For Avanir Pharmaceuticals (AVNR)

Investors in Avanir Pharmaceuticals, Inc. saw new options become available today, for the July expiration.

Arena Pharmaceuticals And 6 More Stocks To Watch

Arena Pharmaceuticals And 6 More Stocks To Watch

Rising short-interest indicates bearishness for the company is building up by investors. Between November 30 2012 and December 14, short-selling [...]

5 Stocks Facing an Earnings Short Squeeze

5 Stocks Facing an Earnings Short Squeeze

You only need to find a few of these stocks in a year to help enhance your portfolio returns -- the gains become so outsized in such a short time frame that your profits add up quickly.

5 Stocks Under $10 Set to Soar Higher

5 Stocks Under $10 Set to Soar Higher

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Avanir Pharmaceuticals' CEO Presents At Canaccord Genuity 32nd Annual Growth Conference (Transcript)

Avanir Pharmaceuticals' CEO Presents At Canaccord Genuity 32nd Annual Growth Conference (Transcript)

Avanir Pharmaceuticals' CEO Presents at Canaccord Genuity 32nd Annual Growth Conference (Transcript)

Avanir Pharmaceuticals' CEO Discusses F3Q12 Results - Earnings Call Transcript

Avanir Pharmaceuticals' CEO Discusses F3Q12 Results - Earnings Call Transcript

Avanir Pharmaceuticals' CEO Discusses F3Q12 Results - Earnings Call Transcript

Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript)

Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript)

Avanir Pharmaceuticals CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript)

Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript)

Avanir Pharmaceuticals' Presents at Deutsche Bank Securities Annual Health Care Conference (Transcript)

Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript

Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript

Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript

8 Stocks Under $10 Moving Higher

8 Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript

Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript

Avanir's CEO Presents at Citi 2012 Global Health Care Conference (Transcript)

AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript

AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript

AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript

Friday's Top 10 Articles, Videos on TheStreet

Friday's Top 10 Articles, Videos on TheStreet

These stories made today's top 10 list of articles and videos on TheStreet.

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

AVANIR Stock Hits New 52-Week Low (AVNR)

AVANIR Stock Hits New 52-Week Low (AVNR)

AVANIR Pharmaceuticals (Nasdaq:AVNR) hit a new 52-week low Wednesday as it is currently trading at $1.97, below its previous 52-week low of $1.98 with 1.2 million shares traded as of 3:29 p.m. ET. Average volume has been 1.5 million shares over the past 30 days.